Altimmune Q4 revenue beats, EPS misses estimates

Altimmune

05/03/2026 12:10

Overview

Biopharmaceutical firm's Q4 revenue beat analyst expectations

Q4 EPS and net income missed analyst estimates

Company strengthened balance sheet with $75 mln direct offering in January

Outlook

Altimmune plans to initiate Phase 3 MASH trial for pemvidutide in 2026

Company expects topline data from RECLAIM Phase 2 AUD trial in Q3 2026

Altimmune strengthens financial position with $75 mln direct offering in January 2026

Result Drivers

BREAKTHROUGH DESIGNATION - Pemvidutide received FDA Breakthrough Therapy Designation for MASH based on positive 24-week data

FINANCIAL STRENGTHENING - Company increased cash reserves to $340 mln through direct offering and ATM facility

CLINICAL PROGRESS - Positive 48-week Phase 2b trial data in MASH with significant improvements in fibrosis and inflammation markers

Company press release: ID:nGNX6RC2wf

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Beat
$26,000
$710 (7 Analysts)
Q4 EPS
Miss
-$0.27
-$0.24 (9 Analysts)
Q4 Net Income
Miss
-$27.36 mln
-$23.31 mln (7 Analysts)
Q4 Income from Operations
Miss
-$28.89 mln
-$24.58 mln (7 Analysts)
Q4 Basic EPS
-$0.27
Q4 Operating Expenses
$28.92 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", 1 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Altimmune Inc is $20.00, about 368.4% above its March 4 closing price of $4.27

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)